Skip to main content
OpenTrials
Completed

NCT Number: NCT06340607

Neohepatic Albumin-Bilirubin Scores on Renal Outcomes in Living-donor Liver Transplantation Recipients

This study investigates the association between post-reperfusion (neohepatic) ALBI scores and post-LT renal outcomes in living-donor LT (LDLT) recipients.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Acute Kidney Injury Chronic Disease Chronic Kidney Diseases Disease Attributes Female Urogenital Diseases Female Urogenital Diseases and Pregnancy Complications Graft Failure Kidney Diseases Male Urogenital Diseases Pathologic Processes Pathological Conditions, Signs and Symptoms Renal Insufficiency Renal Insufficiency, Chronic Urogenital Diseases Urologic Diseases

Age range

18 year–80 year

Sex eligibility

All sexes

Study type

Observational

Primary location

Asan Medical Center

Seoul, Song-pa Gu, 05500, South Korea

About this study

Acute kidney injury (AKI) after liver transplantation (LT) significantly affects patient and graft outcomes. The Albumin-Bilirubin (ALBI) score, an objective and sensitive index of liver function, has potential applicability in predicting outcomes following LT. This study investigates the association between post-reperfusion (neohepatic) ALBI scores and post-LT renal outcomes in living-donor LT (LDLT) recipients.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • living donor liver transplantation recipients (≥18 years)

Exclusion criteria

  • preoperative serum creatinine (sCr) > 1.4 mg/dL, diagnosed CKD or hepatorenal syndrome (HRS), or hemodialysis at baseline

Treatment and study plan

Primary outcomes

  1. acute kidney injury

    Time frame: within 7 days after surgery

    determined by change in sCr according to the Kidney Disease: Improving Global Outcomes (KDIGO) definition (increase in sCr of ≥26.5 mmol litre-1 within 48h or ≥1.5 times baseline within 7 days after surgery

Secondary outcomes

  1. chronic kidney injury

    Time frame: within 1 year after surgery

    when renal function assessed by calculating estimated serum glomerular filtration using the abbreviated modification of diet in renal disease equation was <60 mL/min/1.73 m2 for 3 months or more, irrespective of cause

  2. graft failure

    Time frame: the graft failure at overall period (calculated from the date of surgery to the last follow-up) from the date of surgery (up to 10 years)]

    graft failure

Sponsors and collaborators

Lead sponsor

Asan Medical Center

Other

Registry information

Official study title

Impact of Neohepatic Albumin-Bilirubin Scores on Renal Outcomes Following Living-donor Liver Transplantation: Propensity Score Analysis

Important dates

Study start
2012
Primary completion
2020
Study completion
2022
First posted
Apr 1, 2024
Registry last updated
Apr 1, 2024

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.